“…It is possible that PEP models with longer incubation periods or situations involving real-life exposures would allow sufficient time for the development of active immune responses to vaccination and would protect animals and humans against IRKV infection, as may be inferred from our PrEP experiments. However, short incubation periods may occur after reallife exposures as well (29), and this increases the demand for the development of novel immunoglobulin preparations (including MAbs) for protection against IRKV and other non-RABV lyssaviruses.…”